| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Piperidine-MO-1 targets dopamine receptors in the central nervous system, modulating dopaminergic signaling and affecting the production of DOPAC (3,4-dihydroxyphenylacetic acid), a major dopamine metabolite, in the rat striatum.
|
|---|---|
| ln Vitro |
In vitro receptor binding studies have not been extensively reported for Piperidine-MO-1; however, its in vivo pharmacological profile suggests dopaminergic receptor modulation consistent with its chemical class and patent description.
|
| ln Vivo |
In vivo, Piperidine-MO-1 increases the ED50 of DOPAC in the rat striatum to 68 μmol/kg, indicating modulation of dopamine metabolism and turnover in the brain, with potential implications for understanding dopaminergic function and related neurological disorders.
|
| Enzyme Assay |
The in vitro receptor binding assay for Piperidine-MO-1 would involve incubating the compound with dopamine receptor subtypes (D1, D2, D3, D4, D5) expressed in cell membranes, using radiolabeled ligands (e.g., [3H]spiperone or [3H]SCH23390) to determine binding affinity (Ki) and selectivity via competitive binding experiments.
|
| Cell Assay |
In vitro cell-based functional assays utilize dopamine receptor-expressing cell lines (e.g., CHO or HEK293 cells stably expressing D2 receptors) treated with Piperidine-MO-1, measuring receptor activation via cAMP accumulation assays, β-arrestin recruitment, or calcium flux, with EC50 values determined from concentration-response curves.
|
| Animal Protocol |
In vivo animal experiments involve administering Piperidine-MO-1 to rats via oral or intraperitoneal routes, followed by measurement of DOPAC levels in striatal tissue using HPLC-ECD, with ED50 values calculated from dose-response studies; behavioral assessments may include locomotor activity or prepulse inhibition tests.
|
| ADME/Pharmacokinetics |
Piperidine-MO-1 has a molecular formula C14H21ClFNO2S and molecular weight 321.84 g/mol; it is typically stored at room temperature as a solid powder with purity >95%, and is soluble in appropriate organic solvents for in vitro and in vivo studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for Piperidine-MO-1 are limited; as a research compound, comprehensive toxicity profiles in animals have not been extensively published, and standard safety precautions for handling chemical reagents should be observed.
|
| References | |
| Additional Infomation |
Piperidine-MO-1 is a research compound derived from patent literature, used primarily as a tool for studying dopamine receptor pharmacology and dopaminergic signaling; it has not been approved for clinical use and remains an investigational compound for neurological research applications.
|
| Molecular Formula |
C14H21CLFNO2S
|
|---|---|
| Molecular Weight |
321.838445425034
|
| Exact Mass |
321.096
|
| CAS # |
871351-61-0
|
| PubChem CID |
53379488
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YTWWOWVWYTXBME-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H20FNO2S.ClH/c1-3-16-9-7-11(8-10-16)12-5-4-6-13(14(12)15)19(2,17)18;/h4-6,11H,3,7-10H2,1-2H3;1H
|
| Chemical Name |
1-ethyl-4-(2-fluoro-3-methylsulfonylphenyl)piperidine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1071 mL | 15.5357 mL | 31.0713 mL | |
| 5 mM | 0.6214 mL | 3.1071 mL | 6.2143 mL | |
| 10 mM | 0.3107 mL | 1.5536 mL | 3.1071 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
